Yonhap Infomax NewsSamsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079
Samsung Bioepis Holdings to Expand New Drug Development on Biosimilar Success
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.